Copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Jul 16, 2022; 10(20): 6759-6768
Published online Jul 16, 2022. doi: 10.12998/wjcc.v10.i20.6759
Published online Jul 16, 2022. doi: 10.12998/wjcc.v10.i20.6759
Semaglutide might be a key for breaking the vicious cycle of metabolically associated fatty liver disease spectrum?
Maja Cigrovski Berkovic, Department of Endocrinology, Diabetes, Metabolism and Clinical Pharmacology, Clinical Hospital Dubrava, Zagreb 10000, Croatia
Maja Cigrovski Berkovic, Faculty of Kinesiology, University of Zagreb, Zagreb 10000, Croatia
Tanja Rezic, Department of Endocrinology and Diabetes, Clinical Hospital Dubrava, Zagreb 10000, Croatia
Ines Bilic-Curcic, Department of Endocrinology and Diabetes, University Hospital Centre Osijek, Osijek 31000, Croatia
Anna Mrzljak, Department of Gastroenterology and Hepatology, University Hospital Centre Zagreb, Zagreb 10000, Croatia
Anna Mrzljak, School of Medicine, University of Zagreb, Zagreb 10000, Croatia
Author contributions: Cigrovski Berkovic M made contribution to the conception and design of the study, drafted, and revised the manuscript critically; Rezic T, Bilic-Curcic I, and Mrzljak A collected the data, drafted, and wrote the manuscript; all authors read and approved the final manuscript.
Conflict-of-interest statement: The authors declare no conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Anna Mrzljak, PhD, Adjunct Associate Professor, Department of Gastroenterology and Hepatology, University Hospital Centre Zagreb, Kispaticeva ul 12, Zagreb 10000, Croatia. anna.mrzljak@gmail.com
Received: January 6, 2022
Peer-review started: January 6, 2022
First decision: March 9, 2022
Revised: April 10, 2022
Accepted: May 13, 2022
Article in press: May 13, 2022
Published online: July 16, 2022
Processing time: 179 Days and 9.4 Hours
Peer-review started: January 6, 2022
First decision: March 9, 2022
Revised: April 10, 2022
Accepted: May 13, 2022
Article in press: May 13, 2022
Published online: July 16, 2022
Processing time: 179 Days and 9.4 Hours
Core Tip
Core Tip: The pathogenesis of metabolically associated fatty liver disease (MAFLD) is closely interrelated to type 2 diabetes mellitus (T2DM), with insulin resistance and hyperinsulinemia as key characteristics. Glucagon-like peptide-1 receptor agonists have a favorable effect on glycemic management and weight loss in T2DM patients. Semaglutide is an especially interesting agent with favorable metabolic actions in patients sharing T2DM and MAFLD (but also sole MAFLD) phenotype, available in injectable and oral formulation, thus more attractive for a broader spectrum of patients.